Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.
de Lima M, Champlin RE, Thall PF, Wang X, Martin TG 3rd, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S.
de Lima M, et al. Among authors: jabbour e.
Leukemia. 2008 Feb;22(2):258-64. doi: 10.1038/sj.leu.2405014. Epub 2007 Nov 8.
Leukemia. 2008.
PMID: 17989720
Clinical Trial.